PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31574962-7	2019	The molecular modeling results for analogue 10 showed that the use of the 4-(aminomethyl)benzamide as a flexible linker leads to a favorable overall geometry of the molecule, which allows one to bypass the bulk isoleucine residue and provides the necessary binding to the active center of the T315I-mutant Abl (PDB: 3QRJ).	Isoleucine	211-221	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	306-309	
19557636-2	2009	T315I (Treonine-->Isoleucine) is a mutation in the exon 6 of BCR-ABL gene that makes the protein resistant to kinase inhibitors currently used for treating CML.	Isoleucine	21-31	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	64-71	
17804707-6	2007	The cocrystal structure of T315I Abl kinase domain provides the structural basis for this activity: the inhibitor associates with an active conformation of the kinase domain in the ATP-binding pocket and lacks the steric hindrance imposed by the substitution of threonine by isoleucine.	Isoleucine	275-285	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	33-36	
17164333-6	2006	Through global phosphoproteome analysis, we identified a unique phosphosubstrate signature associated with each drug-resistant allele, including a shift in phosphorylation of two tyrosines (Tyr253 and Tyr257) in the ATP binding loop (P-loop) of BCR-ABL when Thr315 is Ile or Ala.	Isoleucine	268-271	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	245-252	
12149456-2	2002	Mutations of Thr-315 in the Abl kinase domain to Ile (T315I) were previously described in STI-571-resistant patients and likely cause resistance from steric interference with drug binding.	Isoleucine	49-52	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	28-31	
22314840-4	2012	Multiple rational design cycles were utilized to develop a lead peptide with a phenylalanine and alanine replaced by an (N-methyl)phenylalanine and isoleucine, respectively, to attain cytosolic peptidase resistance while maintaining Abl substrate efficacy.	Isoleucine	148-158	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	233-236	
17382017-4	2007	One of the more common mutations results from the substitution of isoleucine for threonine at Abl amino acid position 351, known as the T315I mutation.	Isoleucine	66-76	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	94-97